Moxidectin approved in Ghana for the treatment of river blindness

Melbourne, Australia, 11 December 2024 – Atticus Medical Pty Ltd, a leader in the development of pharmaceuticals with a focus on social impact, is excited to share the news of a pivotal achievement in the fight against neglected tropical diseases. Moxidectin, developed by Atticus Medical’s development partner Medicines Development for Global Health (MDGH), has been approved in Ghana for the treatment of river blindness (onchocerciasis) and will now be made available in a pilot treatment program, beginning in January 2025.

This approval is a testament to the shared mission of both organizations: to address critical global health challenges by delivering affordable, effective treatments to underserved communities. While MDGH already obtained approval of moxidectin for river blindness from the US FDA, the approval announced today is of particular importance as it is the first approval of moxidectin for paediatric use, which is important for other diseases that disproportionately affect children such as scabies and headlice.

Dr John Lambert, Atticus’ General Manager commented:

“Together, MDGH and Atticus are expanding access to life-changing medicines, exemplifying the power of collaboration in global health innovation. This approval in Ghana represents a significant step forward in eliminating river blindness and improving the lives of millions worldwide. We look forward sharing our achievement of more milestones in the future.”

‍

About Atticus Medical Pty Ltd

Atticus Medical is dedicated to developing innovative pharmaceutical solutions that address globally unmet medical needs. With a strong emphasis on research and development, Atticus Medical aims to make a positive impact through its cutting-edge therapies and commitment to affordable healthcare.

‍

For further information, please contact:

Dr John Lambert, General Manager

Atticus Medical Pty Ltd

info@atticusmed.com

www.atticusmed.com

- END

‍